The regulatory framework surrounding the pharmaceutical industry has always been robust and necessary. The drugs produced by this industry have great potential to enhance life quality, but they must be closely monitored to ensure safe and responsible use. The drugs have the potential to save lives, but they can also be incredibly dangerous if not used properly.
The use of social media in the pharmaceutical industry has grown rapidly in recent years. As consumers become more active on social media, it has become critical for pharmaceutical companies to connect with their customers through these platforms.
Today, patients and healthcare providers alike turn to social media for information about drugs and medical conditions
Current regulations limit companies' ability to fully leverage social media due to their lack of coverage of new technologies. That's why there is a growing demand for revamping FDA guidelines to better suit the modern social media landscape. In this blog post, we'll explore the challenges that pharmaceutical companies face when it comes to social media and how revamping FDA guidelines can help them better connect with their customers.
In this article, we will discuss the FDA guidance on social media for pharmaceutical companies, with an emphasis on where the agency has provided guidance and where it has failed to do so. We've included a checklist of actionable steps and a marketing workflow that pharma companies can use as a starting point to tailor their internal Standard Operating Procedures (specific to their use case) and apply the FDA guidance on social media effectively.
FDA Guidance on Social Media for Pharmaceutical Companies
The FDA has provided guidance on social media for pharmaceutical companies in a few areas. The agency has issued draft guidance on using social media for post-marketing surveillance of drug safety, providing clarity on the use of social media to monitor and report adverse events. Additionally, the FDA has issued some guidance on how to present both benefit and risk information regarding drugs on social media platforms that have character limitations, such as Twitter.
Where FDA Has Failed to Provide Guidance
While the FDA has provided some guidance on social media use by pharmaceutical companies, there are still areas where the agency has failed to provide specific guidance. For instance, the agency has not provided guidelines on how to use influencers on social media when promoting drugs. Additionally, the FDA has not guided how to use social media for disease awareness campaigns.
Checklist of Actionable Steps
Pharmaceutical companies should follow these actionable steps to be compliant with the FDA guidance on social media:
Establish clear social media policies and procedures.
Train responsible employees on social media guidelines and regulations.
Develop an internal review process for social media content before sharing.
Ensure social media content is accurate, truthful, and non-misleading.
Monitor social media accounts for adverse events and promptly report findings to the FDA.
Disclose financial relationships with influencers.
Ensure social media campaigns comply with FDA regulations and guidelines.
Update this checklist regularly to remain compliant with the current and any future changes in regulations and guidance.
For the pharmaceutical industry, social media can be a powerful tool for educating and engaging with patients, healthcare providers, and other stakeholders.
Sample Social Media Marketing Workflow for Pharma Companies
Here is a sample social media marketing workflow for pharmaceutical companies, including responsibilities of various units, proposed activities and a list of documents:
1. Marketing
Responsibilities:
Develop a social media marketing plan.
Create social media content.
Activities:
Conduct a social media audit to determine which platforms to use.
Develop a content strategy that aligns with the overall marketing plan.
Create social media content (e.g., blog posts, infographics, videos, etc.).
Documentation:
Social media audit findings report
Content strategy document
Social media content calendar
2. Legal & Regulatory Affairs
Responsibilities:
Review and approve social media content.
Ensure compliance with FDA regulations and guidelines.
Activities:
Develop social media policy and procedures.
Review and approve social media content.
Ensure social media content complies with FDA regulations and guidelines.
Documentation:
Social media policy and procedure document
Social media content review report
3. Medical Affairs
Responsibilities:
Monitor social media accounts for adverse events.
Respond appropriately to inquiries and comments.
Activities:
Develop a social media monitoring plan.
Monitor social media accounts for adverse events.
Respond appropriately to inquiries and comments.
Documentation:
Social media monitoring report
Record of responses to inquiries and comments
Healthcare brands have an ever-growing responsibility to ensure the satisfaction and protection of their consumers. With the proliferation of social media, online reviews, and other digital platforms, it has become increasingly important for healthcare brands to actively listen to the voice of the consumer. Read more here!
A patient using Social Media for drug information
Key takeaway
With the vast amount of information on social media, ensuring consumers have access to accurate and sufficient product safety information can be difficult.
The FDA can enhance consumer safety and effective use of modern social media platforms by updating its guidance, closing the gap and giving straightforward directions to industry stakeholders on social media advertising.
Recommendations for clear communication and transparency in advertising are important to ensure compliance with the regulatory requirements.
Summary
The world of pharmaceuticals is rapidly changing, as is the way in which we communicate and connect with one another. Social media has become an integral part of our daily lives, providing an instant connection to friends, family, and businesses. For the pharmaceutical industry, social media can be a powerful tool for educating and engaging with patients, healthcare providers, and other stakeholders. However, navigating the complex regulatory environment surrounding pharmaceutical marketing on social media can be a significant challenge. The FDA's regulatory guidance on social media is outdated and needs to be updated to keep up with the rapidly changing landscape.
Reading Desk
Disclaimer: The views and opinions expressed on PharmaRead are those of the authors and do not necessarily reflect the official policy or position of any agency or organization. PharmaRead articles are provided for information only with a focus on global health, pharmacy practice, and healthcare systems in Low- and Middle-income Countries (LMICs). Readers should seek expert opinion for use, implementation or application of this knowledge based on their individual circumstances.